Abstract:Cell division cycle-associated 5 (CDCA5) can regulate cell cycle-related proteins to promote the proliferation of cancer cells. The purpose of the present study was to investigate the expression level of CDCA5 in prostate cancer (PCa) and its effect on PCa progression. The signalling pathway by which CDCA5 functions through was also attempted to elucidate. Clinical specimens of PCa patients were collected from the Second Hospital of Tianjin Medical University. The expression level of CDCA5 in cancer tissues and paracancerous tissues from PCa patients was detected by RT-qPCR analysis and IHC. The relationship between the expression level of CDCA5 and the survival rate of PCa patients was analysed using TCGA database. Two stable cell lines (C4-2 and PC-3) with CDCA5 knockdown were established, and the effects of CDCA5 on PCa cell proliferation were detected by MTT and colony formation assays. Flow cytometry was performed to detect the effect of CDCA5 on the PCa cell division cycle, and western blot analysis was used to determine changes in ERK phosphorylation levels after CDCA5 knockdown. The effect of CDCA5 expression on prostate tumour growth was assessed using a mouse xenograft model. The results revealed that the mRNA and protein expression levels of CDCA5 were significantly higher in PCa tissues than in paracancerous tissues. High CDCA5 expression was associated with the prognosis of patients with PCa. CDCA5 expression knockdown significantly reduced the number of PCa cells in mitoses and inhibited their proliferation in vitro and in vivo. When CDCA5 was knocked down, the phosphorylation level of ERK was also reduced. Collectively, CDCA5 was upregulated and affected the prognosis of patients with PCa. Decreased CDCA5 expression inhibited PCa cell proliferation by inhibiting the ERK signalling pathway. Thus, CDCA5 may be a potential therapeutic target for PCa.

CDCA5 is a potent therapeutic target of clear cell renal cell carcinoma

Loss of Cell Division Cycle‑associated 5 Promotes Cell Apoptosis by Activating DNA Damage Response in Clear Cell Renal Cell Carcinoma.

CDCA5-EEF1A1 interaction promotes progression of clear cell renal cell carcinoma by regulating mTOR signaling

RCC1 functions as a tumor facilitator in clear cell renal cell carcinoma by dysregulating cell cycle, apoptosis, and EZH2 stability

Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma

CDCA2 Acts As an Oncogene and Induces Proliferation of Clear Cell Renal Cell Carcinoma Cells.

CDCA5 functions as a tumor promoter in bladder cancer by dysregulating mitochondria-mediated apoptosis, cell cycle regulation and PI3k/AKT/mTOR pathway activation

Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma

Cyclin-dependent Kinase 5 Acts As a Promising Biomarker in Clear Cell Renal Cell Carcinoma

DNMT1-maintained Hypermethylation of Krüppel-like Factor 5 Involves in the Progression of Clear Cell Renal Cell Carcinoma

CDCA5, Transcribed by E2F1, Promotes Oncogenesis by Enhancing Cell Proliferation and Inhibiting Apoptosis Via the AKT Pathway in Hepatocellular Carcinoma

CDCA5 Promotes the Progression of Prostate Cancer by Affecting the ERK Signalling Pathway.

CDCA5 Promotes the Progression of Breast Cancer and Serves As a Potential Prognostic Biomarker

SIRT5 functions as a tumor suppressor in renal cell carcinoma by reversing the Warburg effect

Role of the chemokine family member CCL5 in the development of clear cell renal cell carcinoma

High TXNDC5 Expression Predicts Poor Prognosis in Renal Cell Carcinoma

WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1 accumulation in Myc-dependent and independent pathways

The Comprehensive Analysis Illustrates the Role of CDCA5 in Breast Cancer: an Effective Diagnosis and Prognosis Biomarker

Pro-cancer role of CD276 as a novel biomarker for clear cell renal cell carcinoma

Coiled-coil domain containing 25 (CCDC25) regulates cell proliferation, migration, and invasion in clear cell renal cell carcinoma by targeting the ILK-NF-κB signaling pathway

SNX5 Suppresses Clear Cell Renal Cell Carcinoma Progression by Inducing CD44 Internalization and Epithelial-to-mesenchymal Transition